Gut bacteria could be key to stopping cancer Drug's diarrhea side effect
NCT ID NCT07264985
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looks at why some breast cancer patients get diarrhea from the drug pyrotinib while others don't. Researchers will compare the gut bacteria of 60 patients who develop diarrhea with those who don't. They hope to find specific bacteria that protect against this side effect, which could lead to better ways to manage it in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pyrotinib
What this could lead to
If successful, this could point toward ways to predict or prevent severe diarrhea in breast cancer patients taking pyrotinib.
What could go wrong
This is a small, early observational study with no treatment being tested. It may not find clear links, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hubei Cancer Hospital
Wuhan, Hubei, 430079, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••